A5401 is a master protocol for a series of monoclonal antibodies that will be investigated in Phase 2 and 3 studies. We indicated a plan to enroll 10 participants in the first study.
|Effective start/end date||6/1/20 → 11/30/20|
- University of California at Los Angeles (A5401//3UM1AI068636-14S2)
- National Institute of Allergy and Infectious Diseases (A5401//3UM1AI068636-14S2)